Albumin Fusion Technology
Source: Novozymes Biopharma US Inc.
Our proprietary technology provides molecular fusion of albumin to protein drug candidates for improved half-life and bioavailability. Albumin fusion technology is a natural alternative to PEGylation.
Click Here To Download:
•Brochure: Albumin Fusion Technology
Our proprietary technology provides molecular fusion of albumin to protein drug candidates for improved half-life and bioavailability. Albumin fusion technology is a natural alternative to PEGylation.
•Brochure: Albumin Fusion Technology
•Brochure: Albumin Fusion Technology
Our proprietary technology provides molecular fusion of albumin to protein drug candidates for improved half-life and bioavailability. Albumin fusion technology is a natural alternative to PEGylation.
Combine albufuse with our yeast expression technology and cGMP/Q7-manufacturing services to maximize the benefits of working with us.
Key benefits
- Increased half-life of the active molecule, resulting in:
- Less frequent administration
- Increased bioavailability therefore lowered dosage
- Fewer side effects with improved tolerance
- Competitive production costs
- Specific albumin fusion binding matrices available for improved downstream purification
- Animal-free
- Genetically fused.
Application areas
- Protein drug half-life extension and delivery technologies
- Protein expression.
•Brochure: Albumin Fusion Technology
This website uses cookies to ensure you get the best experience on our website. Learn more